Erratum to: Elevated homocysteine level in first-episode schizophrenia patients - The relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse (Metabolic Brain Disease (2014) DOI: 10.1007/s11011-014-9534-3;Elevated homocysteine level in first-episode schizophrenia patients - The relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

Metabolic Brain Disease

Volumn 29, Issue 3, 2014, Pages 661-670

  Misiak, Blazej ^a   Frydecka, Dorota ^a   Slezak, Ryszard ^a   Piotrowski, Patryk ^a   Kiejna, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cannabis; First episode schizophrenia; Folate; Homocysteine; One carbon metabolism; Vitamin B12

Indexed keywords

CHLORPROMAZINE; CYANOCOBALAMIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CANNABIS ADDICTION; CARBON METABOLISM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FAMILY HISTORY; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPOALPHALIPOPROTEINEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; ONSET AGE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; SCHIZOPHRENIA; SECOND DEGREE RELATIVE; SEX DIFFERENCE; SMOKING; TREATMENT DURATION; BLOOD; COMPLICATION; YOUNG ADULT;

CANNABIS;

ADULT; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LIPOPROTEINS, HDL; MALE; MARIJUANA ABUSE; SCHIZOPHRENIA; VITAMIN B 12; YOUNG ADULT;

EID: 85028202524     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9567-7     Document Type: Erratum

References (74)

1. Araujo JR, Goncalves P, Martel F (2009) Effect of cannabinoids upon the uptake of folic acid by BeWo cells. Pharmacology 83(3):170-176. doi:10.1159/000192587
2. Ayesa-Arriola R, Perez-Iglesias R, Rodriguez-Sanchez JM, Mata I, Gomez-Ruiz E, Garcia-Unzueta M, Martinez-Garcia O, Tabares-Seisdedos R, Vazquez-Barquero JL, Crespo-Facorro B (2012) Homocysteine and cognition in first-episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 262(7):557-564. doi:10.1007/s00406-012-0302-2
3. Bahorik AL, Newhill CE, Queen CC, Eack SM (2013) Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychol Med 1-9. doi:10.1017/S0033291713000548
4. Bicikova M, Hampl R, Hill M, Ripova D, Mohr P, Putz Z (2011) Neuroand immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuroendocrinol Lett 32(2):141-147
5. Bouaziz N, Ayedi I, Sidhom O, Kallel A, Rafrafi R, Jomaa R, Melki W, Feki M, Kaabechi N, El Hechmi Z (2010) Plasma homocysteine in schizophrenia: determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res 179(1):24-29. doi:10.1016/j.psychres.2010.04.008
6. Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS (2012) Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res 11(8):4338-4350. doi:10.1021/pr300459d
7. Casadio P, Fernandes C, Murray RM, Di Forti M (2011) Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev 35(8):1779-1787. doi:10.1016/j.neubiorev.2011.04.007
8. Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, Zhang X, Yang F, Tan Y (2013) Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychoticnaive first-episode patients with schizophrenia. Psychiatry Res 210(3):825-829. doi:10.1016/j.psychres.2013.08.056
9. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G (2012) Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol 213:267-295. doi:10.1007/978-3-642-25758-2-10
10. Davis RE, Midalia ND, Curnow DH (1978) Illegal drugs and nutrition in undergraduate students. Med J Aust 1(11):617-620 (Pubitemid 8399797)
11. de Bree A, Verschuren WM, Blom HJ, Kromhout D (2001) Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 154(2):150-154 (Pubitemid 32643130)
12. Dierkes J, Luley C, Westphal S (2007) Effect of lipid-lowering and antihypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag 3(1):99-108 (Pubitemid 46863141)
13. Dietrich-Muszalska A, Malinowska J, Olas B, Glowacki R, Bald E, Wachowicz B, Rabe-Jablonska J (2012) The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res 37(5):1057-1062. doi:10.1007/s11064-012-0707-3
14. Dong ZQ, Tian YY, Guan X, Wu J, Gu Y, Hu ZQ, Sun XL (2012) Genetic polymorphism of methylenetetrahydrofolate reductase and risk of aggressive behaviour in schizophrenia. Psychiatry Res 200(2-3): 1082. doi:10.1016/j. psychres.2012.07.021
15. El-Hadidy MA, Abdeen HM, Abd El-Aziz SM, Al-Harrass M (2013) C677T methylenetetrahydrofolate reductase gene polymorphism in schizophrenia and bipolar disorder. Psychiatr Genet. doi:10.1097/YPG.0000000000000020
16. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J (2008) Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 98(1-3):47-54. doi:10.1016/j.schres. 2007.09.030 (Pubitemid 350235903)
17. Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zollner SK, Pop-Busui R (2012) Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 32(2):261-265. doi:10.1097/JCP.0b013e3182485888
18. Eren E, Yegin A, Yilmaz N, Herken H (2010) Serum total homocystein, folate and vitamin B12 levels and their correlation with antipsychotic drug doses in adult male patients with chronic schizophrenia. Clin Lab 56(11-12):513-518
19. Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B (2008) Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 98(1-3):302-306. doi:10.1016/j.schres.2007.10.002 (Pubitemid 350245597)
20. Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS (2013) Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 16(5):987-995. doi:10.1017/S1461145712001241
21. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
22. Fujiki Y, Hirashima Y, Seshimo S, Okamoto T, Sugimoto Y, Matsumoto M, Oka T, Kanouchi H (2012) Homocysteine induced SH-SY5Y apoptosis through activation of NADPH oxidase in U251MG cells. Neurosci Res 72(1):9-15. doi:10.1016/j.neures. 2011.09.010
23. Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L, Rodriguez-Jimenez R, Saiz PA, Castro C, Lafuente A, Santabarbara J, Gonzalez-Pinto A, Parellada M, Rubio G, Garcia-Portilla MP, Mico JA, Bernardo M, Leza JC (2013) Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. doi:10.1093/schbul/ sbt001
24. Geller V, Friger M, Sela BA, Levine J (2013) Elevated homocysteine level in siblings of patients with schizophrenia. Psychiatry Res 210(3):769-772. doi:10.1016/j.psychres.2013.08.016
25. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J (2004) Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 161(9):1705-1708. doi:10.1176/appi.ajp.161.9. 1705 (Pubitemid 39201472)
26. Gong J, Pinheiro JC, DeMets DL (2000) Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Control Clin Trials 21(4):313-329 (Pubitemid 30456292)
27. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK (2010) Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diabetes Rep 10(3):209-216. doi:10.1007/s11892-010-0112-8
28. Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 127(1-3):41-45. doi:10.1016/j.schres.2010.12.006
29. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 175(1-2):47-53. doi:10.1016/j.psychres.2009.01.013
30. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261-276 (Pubitemid 18039085)
31. Keating E, Goncalves P, Campos I, Costa F, Martel F (2009) Folic acid uptake by the human syncytiotrophoblast: interference by pharmacotherapy, drugs of abuse and pathological conditions. Reprod Toxicol 28(4):511-520. doi:10.1016/j.reprotox.2009.07.001
32. Knight EM, James H, Edwards CH, Spurlock BG, Oyemade UJ, Johnson AA, West WL, Cole OJ, Westney LS, Westney OE et al (1994) Relationships of serum illicit drug concentrations during pregnancy to maternal nutritional status. J Nutr 124(6 Suppl):973S-980S (Pubitemid 24188049)
33. Kontis D, Theochari E, Fryssira H, Kleisas S, Sofocleous C, Andreopoulou A, Kalogerakou S, Gazi A, Boniatsi L, Chaidemenos A, Tsaltas E (2013) COMTand MTHFR polymorphisms interaction on cognition in schizophrenia: an exploratory study. Neurosci Lett 537:17-22. doi:10.1016/j.neulet.2013.01.012
34. Kumar A, John L, Maity S, Manchanda M, Sharma A, Saini N, Chakraborty K, Sengupta S (2011) Converging evidence of mitochondrial dysfunction in a yeast model of homocysteine metabolism imbalance. J Biol Chem 286(24):21779-21795. doi:10.1074/jbc.M111.228072
35. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159(10):1790-1792
36. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH (2006) Homocysteinereducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60(3):265-269. doi:10.1016/j.biopsych.2005.10.009 (Pubitemid 44093437)
37. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 94(11):5923-5928
38. Ma YY, Shek CC, Wong MC, Yip KC, Ng RM, Nguyen DG, Poon TK (2009) Homocysteine level in schizophrenia patients. Aust N Z J Psychiatry 43(8):760-765. doi:10.1080/00048670903001935
39. Mabrouk H, Douki W, Mechri A, Younes MK, Omezzine A, Bouslama A, Gaha L, Najjar MF (2011) Hyperhomocysteinemia and schizophrenia: case control study. L'Encéphale 37(4):308-313. doi:10.1016/j.encep.2010.12.004
40. Martins JM, Trinca A, Afonso A, Carreiras F, Falcao J, Nunes JS, do Vale S, da Costa JC (2001) Psychoneuroendocrine characteristics of common obesity clinical subtypes. Int J Obes Relat Metab Disord 25(1):24-32 (Pubitemid 32142380)
41. McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, Dougherty GG, Yao JK, Kaddurah-Daouk R (2013) Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS ONE 8(7):e68717. doi:10.1371/journal.pone.0068717
42. McGuffin P, Farmer A, Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48(8):764-770
43. Misiak B, Frydecka D, Piotrowski P, Kiejna A (2013) The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. Epigenomics 5(3):317-329. doi:10.2217/epi.13.22
44. Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1(8636):495 (Pubitemid 19063553)
45. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11(2):143-149. doi:10.1038/sj.mp.4001746 (Pubitemid 43164615)
46. Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162(9):1738-1740. doi:10.1176/appi.ajp.162.9.1738 (Pubitemid 41318246)
47. Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP (2013) Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry 74(1):e94-e99. doi:10.4088/JCP.12m07822
48. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274(19):1526-1533
49. Peerbooms O, Rutten BP, Decoster J, van Os J, Kenis G, De Hert M, van Winkel R (2010) No association between MTHFR C677T or A1298C and age at onset of schizophrenia. Am J Med Genet B, Neuropsychiatr Genet 153B(7):1362-1363. doi:10.1002/ajmg.b.31114, author reply 1361
50. Petronijevic ND, Radonjic NV, Ivkovic MD, Marinkovic D, Piperski VD, Duricic BM, Paunovic VR (2008) Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 32(8):1921-1926. doi:10.1016/j.pnpbp.2008. 09.009
51. Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B, Woods SW, Srihari VH (2011) Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention? Schizophr Res 127(1-3):257-261. doi:10.1016/j.schres. 2010.12.008
52. Pomerleau CS, Majchrzak MJ, Pomerleau OF (1989) Nicotine dependence and the Fagerstrom Tolerance Questionnaire: a brief review. J Subst Abuse 1(4):471-477
53. Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, White T, Clark VP, Fries J, Andreasen NC, Goff DC, Manoach DS (2008a)MTHFR 677C ->T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val -> Met. Proc Natl Acad Sci U S A 105(45):17573-17578. doi:10.1073/pnas.0803727105
54. Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Wong DH, Halsted CH, Goff DC (2008b) Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147B(6):990-995. doi:10.1002/ajmg.b.30684
55. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC (2008c) Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 63(1):42-48. doi:10.1016/j.biopsych.2006.12. 017 (Pubitemid 350234878)
56. Roffman JL, Brohawn DG, Friedman JS, Dyckman KA, Thakkar KN, Agam Y, Vangel MG, Goff DC, Manoach DS (2011a) MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study. Brain Imaging Behav 5(1):65-75. doi:10.1007/s11682-010-9111-2
57. Roffman JL, Nitenson AZ, Agam Y, Isom M, Friedman JS, Dyckman KA, Brohawn DG, Smoller JW, Goff DC, Manoach DS (2011b) A hypomethylating variant of MTHFR, 677C>T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS ONE 6(9):e25253. doi:10.1371/journal.pone.0025253
58. Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC (2013a) Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 39(2):330-338. doi:10.1093/schbul/sbr150
59. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC (2013b) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70(5):481-489. doi:10.1001/jamapsychiatry.2013.900
60. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatr 160(2):284-289 (Pubitemid 41110453)
61. Saetre P, Vares M, Werge T, Andreassen OA, Arinami T, Ishiguro H, Nanko S, Tan EC, Han DH, Roffman JL, Muntjewerff JW, Jagodzinski PP, Kempisty B, Hauser J, Vilella E, Betcheva E, Nakamura Y, Regland B, Agartz I, Hall H, Terenius L, Jonsson EG (2011) Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and age of onset in schizophrenia: a combined analysis of independent samples. Am J Med Genet B Neuropsychiatr Genet 156(2):215-224. doi:10.1002/ajmg.b.31160
62. Saetre P, Grove J, Borglum AD, Mors O, Werge T, Andreassen OA, Vares M, Agartz I, Terenius L, Jonsson EG(2012) Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age at onset of schizophrenia: no consistent evidence for an association in the Nordic population. Am J Med Genet B Neuropsychiatr Genet 159B(8):981-986. doi:10.1002/ajmg.b.32104
63. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24(5):481-485. doi:10.1111/j.1464-5491.2007.02092.x (Pubitemid 46669314)
64. Srisawat U, Reynolds GP, Zhang ZJ, Zhang XR, Arranz B, San L, Dalton CF (2013) Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. Int J Neuropsychopharmacol 1-6. doi:10.1017/S1461145713001375
65. Ulrich CM, Robien K, Sparks R (2002) Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 3(3):299-313. doi:10.1517/14622416.3.3.299 (Pubitemid 34567568)
66. van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, van Os J, De Hert M (2010a) MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol 25(5):270-276. doi:10.1097/YIC.0b013e32833bc60d
67. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M (2010b) MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 121(1-3):193-198. doi:10.1016/j.schres.2010.05.030
68. Vares M, Saetre P, Deng H, Cai G, Liu X, Hansen T, Rasmussen HB, Werge T, Melle I, Djurovic S, Andreassen OA, Agartz I, Hall H, Terenius L, Jonsson EG (2010) Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age of onset in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 153B(2):610-618. doi:10.1002/ajmg.b.31030
69. Wang J, Bai X, Chen Y, Zhao Y, Liu X (2012) Homocysteine induces apoptosis of rat hippocampal neurons by inhibiting 14-3-3epsilon expression and activating calcineurin. PLoS ONE 7(11):e48247. doi:10.1371/journal.pone.0048247
70. Williams J, Farmer AE, Ackenheil M, Kaufmann CA, McGuffin P (1996) A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychol Med 26(4):775-783 (Pubitemid 26244114)
71. Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H, Diao F, Wang J, Zheng L, Zhao J, Zhang J (2013) The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res 150(1):157-162. doi:10.1016/j.schres.2013.07.051
72. Wysokinski A, Kloszewska I (2013) Homocysteine levels in patients with schizophrenia on clozapine monotherapy. Neurochem Res 38(10):2056-2062. doi:10.1007/s11064-013-1113-1
73. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325(7374):1199
74. Zhang Y, Yan H, Tian L, Wang F, Lu T, Wang L, Yan J, Liu Q, Kang L, Ruan Y, Zhang D, Yue W (2013) Association of MTHFR C677T polymorphismwith schizophrenia and its effect on episodicmemory and gray matter density in patients. Behav Brain Res 243:146-152. doi:10.1016/j.bbr.2012.12.061